Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Completed 3Recruiting 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 51Lung Neoplasms 40Carcinoma, Non-Small-Cell Lung 28Neoplasm Metastasis 25Brain Neoplasms 23Pancreatic Neoplasms 22Lymphoma, Large B-Cell, Diffuse 22Glioma 20Breast Neoplasms 20Squamous Cell Carcinoma of Head and Neck 17Glioblastoma 17Multiple Myeloma 16Colorectal Neoplasms 14Carcinoma, Renal Cell 13Urinary Bladder Neoplasms 12Mouth Neoplasms 11Lymphoma, Mantle-Cell 11Triple Negative Breast Neoplasms 10Oropharyngeal Neoplasms 10Melanoma 10Leukemia, Lymphocytic, Chronic, B-Cell 10Carcinoma 10Ovarian Neoplasms 9Laryngeal Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Nasopharyngeal Carcinoma 8Lymphoma, Follicular 8Leukemia, Myeloid, Acute 8Lymphoma, B-Cell 7Hypopharyngeal Neoplasms 7

Interventions

Cyclophosphamide 21venetoclax 18pembrolizumab 16Dexamethasone 16fludarabine 14Cytarabine 13Gemcitabine 9pomalidomide 8Rituximab 8Carboplatin 8Azacitidine 8glofitamab 7fludarabine phosphate 7Lenalidomide 7Immunotherapy, Adoptive 7selinexor 6Paclitaxel 6Injections 6Granulocyte Colony-Stimulating Factor 6Cisplatin 6daratumumab 5Temozolomide 5Oxaliplatin 5Bevacizumab 5zanubrutinib 4ruxolitinib 4Surgical Procedures, Operative 4Nivolumab 4Drug Therapy 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Recurrence × Magnetic Resonance Spectroscopy × Clear all
NCT06868433 2026-03-04

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Emory University

Phase 1 Recruiting
40 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT06527027 2025-12-30

LN-RADS, RECIST 1.1 and Node-RADS Classification in the Assessment of Lymph Nodes

Copernicus Memorial Hospital

Phase NA Recruiting
1,000 enrolled

Lymphadenopathy, Lymphatic Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡